Would suicide gene therapy solve the 'T-cell dilemma' of allogeneic bone marrow transplantation?
Cohen
J L
JL
Génopoiétic, 22 rue Esquirol, Paris F-75013, France.
Boyer
O
O
Klatzmann
D
D
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000628:therapy; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology*; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015774:Ganciclovir / Q000494:pharmacology / Q000627:therapeutic use; D015316:Genetic Therapy / Q000379:methods*; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control; D018259:Herpesvirus 1, Human / Q000235:genetics; D006801:Humans; D008212:Lymphocyte Depletion / Q000379:methods; D051379:Mice; D008822:Mice, Transgenic; D013601:T-Lymphocytes / Q000187:drug effects / Q000201:enzymology / Q000276:immunology*; D013937:Thymidine Kinase / Q000235:genetics; D014162:Transfection; D014170:Transformation, Genetic
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D013937:Thymidine Kinase; D015774:Ganciclovir